A SYSTEMATIC REVIEW OF HEALTH-STATE UTILITY VALUES IN ADVANCED GASTRIC, OESOPHAGEAL, OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA

被引：0
|
作者：
Carter, Cuyun G. [1 ]
King, D. T. [2 ]
Mitchell, S. A. [2 ]
Hess, L. M. [1 ]
Taipale, K. L. [3 ]
Kiiskinen, U. [3 ]
Rajan, N. [4 ]
Novick, D. [5 ]
Liepa, A. M. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Abacus Int, Bicester, Oxon, England
[3] Oy Eli Lilly Finland Ab, Helsinki, Finland
[4] Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
[5] Eli Lilly & Co, Windlesham, Surrey, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN141
引用
收藏
页码：A92 / A92
页数：1
相关论文
共 50 条
  • [31] A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
    Scott, L. C.
    Yao, J. C.
    Benson, A. B., III
    Thomas, A. L.
    Falk, S.
    Mena, R. R.
    Picus, J.
    Wright, J.
    Mulcahy, M. F.
    Ajani, J. A.
    Evans, T. R. J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 363 - 370
  • [32] Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
    Longo Munoz, F.
    Jorge Fernandez, M.
    Tur, R. Yaya
    Diaz, S.
    Ortega, M.
    Dilla, T.
    Molero, A.
    Cervera, J. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [33] A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
    L. C. Scott
    J. C. Yao
    A. B. Benson
    A. L. Thomas
    S. Falk
    R. R. Mena
    J. Picus
    J. Wright
    M. F. Mulcahy
    J. A. Ajani
    T. R. J. Evans
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 63 : 363 - 370
  • [34] Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (0) and gastro-oesophageal junction (GOJ) cancer
    Cheong, KA
    Chrystal, K
    Forshaw, M
    Gossage, J
    Galani, E
    Botha, A
    Mason, R
    Harper, PG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 347S - 347S
  • [35] ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA
    Luo, X.
    Peng, L.
    Tan, C.
    Wan, X.
    Zeng, X.
    [J]. VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [36] A PHASE I TRIAL OF BORTEZOMIB IN COMBINATION WITH EPIRUBICIN, CARBOPLATIN AND CAPECITABINE (ECARBOX) IN ADVANCED GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GOJ) ADENOCARCINOMA
    Turkington, R. C.
    Purcell, C.
    Wilson, R. H.
    Eatock, M. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 249 - 249
  • [37] Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction
    Hulscher, JBF
    van Lanschot, JJB
    [J]. DIGESTIVE SURGERY, 2005, 22 (03) : 130 - 134
  • [38] THE RELEVANCE OF THE SIEWERT CLASSIFICATION IN THE ERA OF MULTIMODAL THERAPY FOR ADENOCARCINOMA OF THE GASTRO-OESOPHAGEAL JUNCTION
    Noble, F.
    Bailey, I. S.
    Kelly, J. J.
    Byrne, J. P.
    Underwood, T. J.
    [J]. GUT, 2012, 61 : A313 - A313
  • [39] Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction
    Lagarde, S. M.
    Reitsma, J. B.
    de Castro, S. M. M.
    ten Kate, F. J. W.
    Busch, O. R. C.
    van Lanschot, J. J. B.
    [J]. BRITISH JOURNAL OF SURGERY, 2007, 94 (11) : 1361 - 1368
  • [40] Clinicopathologic and survival differences between adenocarcinoma of the distal oesophagus and gastro-oesophageal junction
    Paredes, Steven Ronald
    Wong, Ngar Lok Joshua
    Khoma, Oleksandr
    Park, Jin-Soo
    Kennedy, Catherine
    Van der Wall, Hans
    Falk, Gregory Leighton
    [J]. ANZ JOURNAL OF SURGERY, 2022, 92 (09) : 2137 - 2142
12345